Compare SUVEN LIFE with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES CADILA HEALTHCARE SUVEN LIFESCIENCES/
CADILA HEALTHCARE
 
P/E (TTM) x 2.3 28.6 8.1% View Chart
P/BV x 0.5 3.4 15.8% View Chart
Dividend Yield % 4.3 1.0 421.2%  

Financials

 SUVEN LIFESCIENCES   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
CADILA HEALTHCARE
Mar-19
SUVEN LIFESCIENCES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs338432 78.1%   
Low Rs169306 55.3%   
Sales per share (Unadj.) Rs52.1128.6 40.5%  
Earnings per share (Unadj.) Rs6.818.5 36.8%  
Cash flow per share (Unadj.) Rs8.624.4 35.1%  
Dividends per share (Unadj.) Rs1.503.50 42.9%  
Dividend yield (eoy) %0.60.9 62.4%  
Book value per share (Unadj.) Rs65.3101.5 64.4%  
Shares outstanding (eoy) m127.281,023.74 12.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.9 169.3%   
Avg P/E ratio x37.119.9 186.4%  
P/CF ratio (eoy) x29.615.1 195.4%  
Price / Book Value ratio x3.93.6 106.7%  
Dividend payout %22.018.9 116.4%   
Avg Mkt Cap Rs m32,272378,170 8.5%   
No. of employees `0001.112.4 8.7%   
Total wages/salary Rs m66121,241 3.1%   
Avg. sales/employee Rs Th6,132.210,585.0 57.9%   
Avg. wages/employee Rs Th611.11,707.8 35.8%   
Avg. net profit/employee Rs Th803.51,526.5 52.6%   
INCOME DATA
Net Sales Rs m6,635131,656 5.0%  
Other income Rs m2422,011 12.0%   
Total revenues Rs m6,877133,667 5.1%   
Gross profit Rs m1,60429,731 5.4%  
Depreciation Rs m2215,986 3.7%   
Interest Rs m381,935 1.9%   
Profit before tax Rs m1,58723,821 6.7%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7185,303 13.5%   
Profit after tax Rs m86918,987 4.6%  
Gross profit margin %24.222.6 107.1%  
Effective tax rate %45.222.3 203.2%   
Net profit margin %13.114.4 90.9%  
BALANCE SHEET DATA
Current assets Rs m6,23284,981 7.3%   
Current liabilities Rs m1,49073,425 2.0%   
Net working cap to sales %71.58.8 814.3%  
Current ratio x4.21.2 361.4%  
Inventory Days Days8675 116.0%  
Debtors Days Days83110 75.4%  
Net fixed assets Rs m4,043133,493 3.0%   
Share capital Rs m1271,024 12.4%   
"Free" reserves Rs m8,183102,839 8.0%   
Net worth Rs m8,310103,863 8.0%   
Long term debt Rs m1839,497 0.0%   
Total assets Rs m10,389234,831 4.4%  
Interest coverage x43.113.3 323.8%   
Debt to equity ratio x00.4 0.6%  
Sales to assets ratio x0.60.6 113.9%   
Return on assets %8.78.9 98.0%  
Return on equity %10.518.3 57.2%  
Return on capital %19.518.3 106.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62248,404 11.6%   
Fx outflow Rs m1,79911,593 15.5%   
Net fx Rs m3,82236,811 10.4%   
CASH FLOW
From Operations Rs m35628,823 1.2%  
From Investments Rs m-279-57,387 0.5%  
From Financial Activity Rs m-22518,846 -1.2%  
Net Cashflow Rs m-148-7,105 2.1%  

Share Holding

Indian Promoters % 63.4 74.8 84.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.3 -  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 11.0 331.8%  
Shareholders   37,287 44,069 84.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; IT and Metal Stocks Under Pressure(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is down 0.4%.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

Get Rich as the
Market Rebounds from Covid-19

Coronavirus Rebound
Get this special guide, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


May 29, 2020 11:59 AM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - AJANTA PHARMA COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS